Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on May 15, 2019. The filing discloses the entry into a material definitive agreement to secure a new revolving line of credit to support its operations.
Key Financial Metrics and Obligations
- Debt Facility: Entered into a revolving line of credit with Pacific Western Bank for up to $50.0 million.
- Maturity Date: April 15, 2022.
- Interest Rate: Variable. The rate is the greater of (i) 1.25% below the Prime Rate or (ii) 4.25% if the company maintains a daily cash balance of at least $25.0 million at the Bank. If the balance is below $25.0 million, the rate is the greater of (i) 0.25% above the Prime Rate or (ii) 5.75%.
- Fees: A $25,000 closing fee was paid. An unused fee of 0.50% per annum on the unused portion is required quarterly, unless the $25.0 million daily cash balance is maintained.
- Early Termination Fee: 1.0% of the Revolving Line if terminated prior to maturity.
- Collateral: Security interest granted in substantially all assets, excluding intellectual property (though rights to payment from IP sales/licensing are included).
- Liquidity Requirement: The company must maintain unrestricted cash and cash equivalents at the Bank equal to at least the amount borrowed plus any other outstanding obligations to the Bank.
Material Changes
This filing represents a new material financial obligation. The company has not provided comparative financial data (revenue, profit, or cash flow) for the current period versus prior periods within this specific 8-K filing.
Guidance, Risks, and Covenants
- Covenants: The agreement includes restrictive covenants limiting mergers, acquisitions, asset dispositions, incurrence of additional indebtedness, asset encumbrances, and dividend payments, subject to specified exceptions.
- Events of Default: Includes material adverse change. Upon default, the bank may declare obligations immediately due and increase the interest rate by an additional 3.00%.
- Prepayment: Advances may be prepaid at any time without penalty or premium.
Investor Verification Checklist
- Verify the company's current cash balance to determine if the lower interest rate tier (4.25% floor) is applicable.
- Review the full Loan and Security Agreement (Exhibit 10.1) for specific definitions of "material adverse change" and covenant exceptions.
- Confirm the company's ability to maintain the required cash sweep balance equal to outstanding borrowings.
- Assess the impact of the 0.50% unused fee on future cash flows if the line remains largely undrawn.